Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis

NCT03897192 — Completed, 14 participants, Changhua Christian Hospital

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor

Registry	NCT03897192
Status	Completed
Study type	Observational
Enrollment	14 (Actual)
Sponsor	Changhua Christian Hospital (Other)
Conditions	Punctate Inner Choroidopathy
Interventions	Bevacizumab (Drug)
Dates	start 2018-10-01, primary completion 2019-01-31, completion 2019-03-20, first posted 2019-04-01, last updated 2019-04-01
Locations	1 site in Taiwan

-Summary

To report the long term prognosis in patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR).

Expand all sections · Collapse all

+Arms and interventions

Bevacizumab (Drug): Anti-vascular endothelial growth factor (VEGF)

+Outcome measures

Primary outcomes

Wilcoxon Signed-Rank test [Baseline, 4 year]: A statistical comparison of average of different time point

Secondary outcomes

visual acuity [Baseline, 6 month, 12 month, 24 month, 36 month, 48 month]: visual acuity change in logMAR in different time point

+Eligibility

Sex: All, ages: 20 Years to 50 Years

Inclusion Criteria:

* Patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR).
* Follow up over 4 years.

Exclusion Criteria:

* Patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) without zonal outer retinopathy (ZOR).

+Locations (1)

Facility	City	Country	Status
Changhua Christian Hospital	Changhua	Taiwan